A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Trial Investigating the Efficacy and Safety of Clobetasol Propionate Cream, 0.025% in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days

Seemal Desai,Zoe Draelos,J Mark Jackson,Steve Feldman

doi:10.25251/skin.5.supp.33

Abstract

N/A

Highlights

Topical corticosteroids continue to play a vital role in the management of numerous inflammatory skin conditions
This study reports the e cacy and safety of clobetasol propionate cream 0.025% formulated with diethylene glycol monoethyl ether in adult patients with moderate to severe plaque psoriasis
To study the efficacy and safety of a lower-concentration clobetasol propionate cream, 0.025% formulated with diethylene glycol monoethyl ether compared to vehicle for the topical treatment of adult moderate to severe plaque psoriasis

Summary

Introduction

Topical corticosteroids continue to play a vital role in the management of numerous inflammatory skin conditions. The management of potential side e ects remains a challenge, especially when introducing molecules with a higher potency. An alternative concentration of clobetasol propionate cream 0.025% (Impoyz®) formulated with diethylene glycol monoethyl ether (Transcutol P®), a drug solubility and permeation enhancer, demonstrated a lower degree of systemic exposure compared to the traditional 0.05% concentration of clobetasol propionate cream.. This study reports the e cacy and safety of clobetasol propionate cream 0.025% formulated with diethylene glycol monoethyl ether in adult patients with moderate to severe plaque psoriasis. To study the efficacy and safety of a lower-concentration clobetasol propionate cream, 0.025% formulated with diethylene glycol monoethyl ether compared to vehicle for the topical treatment of adult moderate to severe plaque psoriasis

Methods

Results

Conclusion